Get the Stockscreener App
11.80
3.24%
0.37
Elicio Therapeutics Inc stock is traded at $11.80, with a volume of 360.50K.
It is up +3.24% in the last 24 hours and up +26.61% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$11.43
Open:
$11.68
24h Volume:
360.50K
Relative Volume:
5.55
Market Cap:
$192.79M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.4611
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+19.92%
1M Performance:
+26.61%
6M Performance:
+38.17%
1Y Performance:
+164.57%
1-Day Range:
$11.39
$11.97
1-Week Range:
$11.00
$12.42
52-Week Range:
$3.70
$12.42
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
11.80 | 192.46M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Is a relief rally coming for Elicio Therapeutics Inc. holdersJuly 2025 Sentiment & Stock Portfolio Risk Management - Newser
What to expect from Elicio Therapeutics Inc. in the next 30 daysWeekly Loss Report & AI Based Buy/Sell Signal Reports - Newser
Tick level data insight on Elicio Therapeutics Inc. volatilityPortfolio Profit Report & Reliable Price Breakout Alerts - Newser
Why Elicio Therapeutics Inc. is moving todayVolume Spike & Proven Capital Preservation Methods - Newser
Can machine learning forecast Elicio Therapeutics Inc. recovery2025 Performance Recap & Consistent Income Trade Ideas - Newser
Signal strength of Elicio Therapeutics Inc. stock in tech scanners2025 Momentum Check & Free Community Supported Trade Ideas - Newser
Forecasting Elicio Therapeutics Inc. price range with options dataEarnings Overview Summary & Free High Return Stock Watch Alerts - Newser
Building trade automation scripts for Elicio Therapeutics Inc.July 2025 PreEarnings & Long Hold Capital Preservation Plans - Newser
Using Bollinger Bands to evaluate Elicio Therapeutics Inc.July 2025 PreEarnings & Long Hold Capital Preservation Plans - Newser
Analyzing Elicio Therapeutics Inc. with risk reward ratio chartsTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Can technical indicators confirm Elicio Therapeutics Inc.’s reversalMarket Growth Review & Low Risk High Reward Ideas - Newser
News impact scoring models applied to Elicio Therapeutics Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsEarnings Recap Report & Advanced Swing Trade Entry Alerts - Newser
What recovery options are there for Elicio Therapeutics Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - Newser
Is it too late to sell Elicio Therapeutics Inc.Earnings Growth Summary & Reliable Price Breakout Signals - Newser
Elicio Therapeutics Soars 21.92% to 52-Week High Amid Biotech Sector Surge – What’s Fueling This Rally? - AInvest
Elicio To Report Key Phase II Data On Cancer Immunotherapy Vaccine In Q4; Stock Hits New High - RTTNews
Elicio Therapeutics Soars 19.15% Intraday: Biotech Breakthroughs and Gamma-Driven Options Ignite Speculative Frenzy - AInvest
Elicio Therapeutics Soars 17.7%: What's Fueling This Biotech Surge? - AInvest
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
What does recent volatility data suggest for Elicio Therapeutics Inc.2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Risk vs reward if holding onto Elicio Therapeutics Inc.2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Evaluating Elicio Therapeutics Inc. with trendline analysis2025 Market Outlook & Risk Managed Investment Signals - Newser
Is Elicio Therapeutics Inc. impacted by rising rates2025 Performance Recap & Community Verified Swing Trade Signals - thegnnews.com
How hedge fund analytics apply to Elicio Therapeutics Inc. stockMarket Performance Recap & Weekly Return Optimization Alerts - Newser
Analyzing recovery setups for Elicio Therapeutics Inc. investorsBreakout Watch & Safe Swing Trade Setups - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - Newser
What makes Elicio Therapeutics Inc. stock price move sharplyJuly 2025 Momentum & Daily Stock Momentum Reports - thegnnews.com
Market reaction to Elicio Therapeutics Inc.’s recent news2025 Momentum Check & Weekly Sector Rotation Insights - Newser
Is Elicio Therapeutics Inc. Stock Overbought or Oversold RSI Indicator Analysis2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
Applying chart zones and confluence areas to Elicio Therapeutics Inc.July 2025 Volume & Risk Managed Investment Signals - Newser
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):